Edgewise Therapeutics (EWTX) Income from Non-Controlling Interests (2021 - 2026)
Edgewise Therapeutics (EWTX) reported Income from Non-Controlling Interests of -$929000.0 for Q1 2026, down 4789.47% on a YoY basis from $19810.3 in Q1 2025, and down 3770.83% sequentially from -$24000.0 in Q4 2025.
Edgewise Therapeutics (EWTX) Income from Non-Controlling Interests (2021 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$929000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 4789.47% year-over-year to -$929000.0; the trailing twelve-month figure through Mar 2026 stood at -$653000.0 (down 151.74% YoY), and the FY2025 full-year result was $257000.0, down 19.94% from the prior year.
- Income from Non-Controlling Interests eased to -$929000.0 in Q1 2026, from -$24000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $2.1 million in Q3 2024 to a low of -$1.4 million in Q1 2022.
- A 5-year average of $15411.8 and a median of -$24000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests jumped 1644.44% in 2022 and sank 4789.47% in 2026, its largest moves.
- Tracing EWTX's Income from Non-Controlling Interests over 5 years: stood at $824000.0 in 2022, then sank by 36.53% to $523000.0 in 2023, then sank by 220.65% to -$631000.0 in 2024, then soared by 96.2% to -$24000.0 in 2025, then tumbled by 3770.83% to -$929000.0 in 2026.
- Business Quant data shows EWTX's Income from Non-Controlling Interests at -$929000.0 in Q1 2026, -$24000.0 in Q4 2025, and $497000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Edgewise Therapeutics | 4.54 Bn | 4.54 Bn | - | -929,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -929,000.00 |
| Dec 31, 2025 | -24,000.00 |
| Sep 30, 2025 | 497,000.00 |
| Jun 30, 2025 | -197,000.00 |
| Mar 31, 2025 | -19,000.00 |
| Dec 31, 2024 | -631,000.00 |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | -193,000.00 |
| Mar 31, 2024 | -960,000.00 |
| Dec 31, 2023 | 523,000.00 |
| Sep 30, 2023 | 123,000.00 |
| Jun 30, 2023 | -296,000.00 |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 824,000.00 |
| Sep 30, 2022 | 157,000.00 |
| Jun 30, 2022 | -404,000.00 |
| Mar 31, 2022 | -1.42 Mn |
| Dec 31, 2021 | -490,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 21,000.00 |